OKUR - OnKure Therapeutics Inc Market Capitalization to Book Value Ratio

Corporate emblem and logo of onkuretherapeutics.com (OKUR)

The business model of OnKure Therapeutics Inc (OKUR) relies on the success of PI3Kα inhibitors and the safety of combination therapy for solid tumors. Since the company develops anticancer agents, its growth is independent of market cycles, and the metric stands at 0.62. The price trajectory shown below complements the asset analysis. The firm is currently fighting for leadership in targeted therapy, overcoming tumor resistance to protect its patents.

OnKure Therapeutics (OKUR) - Market Capitalization to Book Value Ratio from 10/08/2024 to 10/31/2026

Analytical breakdowns and data insights for company OnKure Therapeutics Inc (OKUR)

- market value and analyst target forecast:
Price Chart onkuretherapeutics.com|OKUR - Fair Value Consensus
- market capitalization statistics:
Market Capitalization OnKure|OKUR - Real Price to Acquire Entire Company
- balance sheet net asset value indicators:
Book Value per Share OnKure Therapeutics|OKUR - Book Capitalization|Market Value to Book Value Ratio onkuretherapeutics.com|OKUR - Total Business Assets
- debt and liquidity details:
Total Debt to Capital OnKure Therapeutics Inc|OKUR - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital onkuretherapeutics.com|OKUR - Company Cumulative Debt|Debt to Book Capitalization Ratio OnKure|OKUR - Company Long-Term Loans and Borrowings|Company Current Liabilities OnKure Therapeutics|Quick Ratio onkuretherapeutics.com
- earnings and valuation multiples indicators:
OKUR - Net Income
Comprehensive company analysis:OnKure Therapeutics Inc
Flagship merchandise of OnKure Therapeutics Inc

The virtual model of OnKure Therapeutics Inc (OKUR), which delegates molecule synthesis to external vendors, establishes intellectual property as the primary asset. This indicator compares the business's market value with its net assets, revealing the gap between objective capital and investor expectations. By analyzing this chart of the market cap to book value multiple, one can assess the extent of the premium paid for future patents. A declining ratio indicates an erosion of confidence in the value of the assets. Consequently, this metric determines the current market premium over the company's balance sheet.

Who OnKure Therapeutics Inc competes with

BeiGene Ltd (ONC) - Market Value to Book Value Ratio|halozyme.com - Market Value to Book Value|RVMD (Revolution Medicines, Inc.) - Market Capitalization to Book Value Ratio|Market Cap to Net Assets Ratio Ascentage Pharma Group International (AAPG)|Market Capitalization to Book Value Ratio CGON|Market Capitalization to Book Value Ratio UroGen Pharma Corp (URGN)|Market Value to Book Value Ratio Bicara Therapeutics Inc. BCAX|PSNL: Capitalization to Book Value Ratio|Erasca - Market Capitalization to Book Value Ratio|Delcath Systems Inc (DCTH) - Market Cap to Net Assets Ratio|YMAB: Market Capitalization to Book Value Ratio|Market-to-Book Ratio Aura Corp (AURA)|Market Value to Book Value Ratio Candel Therapeutics Inc.|ARAY: Market Value to Book Value|Market Cap to Net Assets Ratio SLS (SELLAS Life Sciences)|ACTU (Actuate Therapeutics Inc.) - Market Value to Book Value|Market Capitalization to Book Value Ratio CTOR (Citius Oncology, Inc)|HURA - Market Cap to Net Assets Ratio|TARA: Market Cap to Net Assets Ratio|FATE - Market Capitalization to Book Value Ratio|aadibio.com (WHWK) - Market Value to Book Value Ratio|TScan Therapeutics, Inc. - Market Value to Book Value|CSBR (Champions Oncology Inc) - Market Capitalization to Book Value Ratio|Market-to-Book Ratio XBiotech USA XBIT|Market Value to Book Value Ratio CEL-SCI Corporation (CVM)|OSTX - Market-to-Book Ratio|Market Value to Book Value Ratio Radiopharm Theranostics RADX|ARTV: Capitalization to Book Value Ratio|ANL - Market Value to Book Value Ratio|VERU - Market Capitalization to Book Value Ratio|TPST (Tempest Therapeutics) - Market Cap to Net Assets Ratio|Xilio Therapeutics (XLO) - Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio Renovaro Biosciences|MURA: Market Value to Book Value|Market Capitalization to Book Value Ratio KAPA|GDTC - Market-to-Book Ratio|Curis - Market Cap to Net Assets Ratio|Market Value to Book Value APLM|THAR: Market Cap to Net Assets Ratio|Advanced Biomed Inc - Market Cap to Book Value Multiple|GNPX: Market Capitalization to Book Value Ratio|Calidi Biotherapeutics, Inc. - Market Value to Book Value|SBFM (Sunshine Biopharma) - Market Capitalization to Book Value Ratio|Market-to-Book Ratio Xenetic Bio XBIO|Market Value to Book Value Ratio Salarius Pharmaceuticals, Inc. (SLRX)|PPBT (Purple Biotech Ltd) - Market Value to Book Value|Market Capitalization to Book Value Ratio AONC (American Oncology Network, Inc.)|Market Capitalization to Book Value Ratio BeiGene Ltd BGNE|CKPT - Market Value to Book Value Ratio|Market Capitalization to Net Assets ELEV|ICAD: Market Capitalization to Book Value Ratio|Market-to-Book Ratio Ikena Oncology (IKNA)|Market Cap to Net Assets Ratio NTBL|Market Capitalization to Book Value Ratio Viracta|Market Cap to Net Assets Ratio MOR (MorphoSys AG)|Market Cap to Book Value Multiple NAYA|Market Capitalization to Book Value Ratio AAPGV (Ascentage Pharma)